Grace Therapeutics Reports $2.1 Million Second-Quarter Net Loss; Cash Runway Through 2028

Grace Therapeutics reported a net loss of $2.1 million, or $0.11 per share, for the three months ended September 30, 2026, compared with a $0.9 million loss a year earlier. Research and development expenses rose to $0.9 million, while general and administrative expenses declined to $1.4 million. Th…